Predictors of efficacy in lithium augmentation for treatment-resistant depression
- PMID: 20089312
- DOI: 10.1016/j.jad.2009.12.025
Predictors of efficacy in lithium augmentation for treatment-resistant depression
Abstract
Background: Lithium augmentation is widely applied for treatment-resistant depression, however, the clinical predictors of its efficacy regarding polarity and bipolarity are unknown.
Methods: We retrospectively examined the predictive value of clinical variables in 79 depressed patients who underwent lithium augmentation after failure to respond to antidepressant monotherapy. Lithium augmentation efficacy was evaluated by Clinical Global Impression Improvement assessment 4 to 8 weeks after initiating lithium administration; subjects with scores of 1 and 2 were defined as responders, and those with scores of 3 to 7 as non-responders. Clinical variables, including demographic and diagnostic variables, psychiatric medication, and clinical variables, were compared between groups. The bipolarity of patients with major depressive disorder as a final diagnosis was evaluated in association with the lithium augmentation efficacy. Data were analyzed using a chi-square test or Fisher's test.
Results: The lithium augmentation efficacy rate was 41% among 79 enrolled patients (14 dropped out, 32 responders, and 33 non-responders). Lithium augmentation was significantly more effective for patients with a final diagnosis of bipolar disorder than with major depressive disorder (p=0.03). Subjects with more than three major depressive episodes showed a significant response to lithium augmentation (p=0.004). The rate of a family history of major depressive disorder/bipolar disorder in a first-degree relative was significantly higher in responders (34%) than in non-responders (7%, p=0.01), consistent with the association between the efficacy of lithium augmentation and bipolarity in major depressive disorder (responders=27% vs. non-responders=3%, p=0.03).
Limitation: The study was retrospective and severity was not analyzed.
Conclusion: Bipolar disorder, frequency of major depressive episodes, and family history of major depressive disorder/bipolar disorder in a first-degree relative were detected as predictors of lithium augmentation efficacy. Among them, family history of major depressive disorder/bipolar disorder in a first-degree relative was the most reliable predictor of lithium augmentation efficacy for bipolar disorder and major depressive disorder.
2010 Elsevier B.V. All rights reserved.
Similar articles
-
Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.J Affect Disord. 2005 Feb;84(2-3):243-9. doi: 10.1016/j.jad.2004.01.006. J Affect Disord. 2005. PMID: 15708422
-
Antidepressant treatment practice in the face of STAR*D and STEP-BD.Bipolar Disord. 2008 Dec;10(8):973-4. doi: 10.1111/j.1399-5618.2008.00631.x. Bipolar Disord. 2008. PMID: 19594512 No abstract available.
-
Treatment of bipolar depression.Psychiatr Clin North Am. 2005 Jun;28(2):349-70, vii. doi: 10.1016/j.psc.2005.02.003. Psychiatr Clin North Am. 2005. PMID: 15826736 Review.
-
Mirtazapine-induced manic switch in adolescent unipolar depression.Aust N Z J Psychiatry. 2008 Dec;42(12):1070-1. Aust N Z J Psychiatry. 2008. PMID: 19031640 No abstract available.
-
Is lithium still worth using? An update of selected recent research.Harv Rev Psychiatry. 2002 Mar-Apr;10(2):59-75. Harv Rev Psychiatry. 2002. PMID: 11897747 Review.
Cited by
-
Polygenic contributions to lithium augmentation outcomes in antidepressant non-responders with unipolar depression.medRxiv [Preprint]. 2025 Jan 23:2025.01.22.25320940. doi: 10.1101/2025.01.22.25320940. medRxiv. 2025. PMID: 39974118 Free PMC article. Preprint.
-
Lack of Autophagy Induction by Lithium Decreases Neuroprotective Effects in the Striatum of Aged Rats.Pharmaceutics. 2021 Jan 21;13(2):135. doi: 10.3390/pharmaceutics13020135. Pharmaceutics. 2021. PMID: 33494241 Free PMC article.
-
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.Int J Neuropsychopharmacol. 2020 Dec 3;23(9):587-625. doi: 10.1093/ijnp/pyaa033. Int J Neuropsychopharmacol. 2020. PMID: 32402075 Free PMC article.
-
The clinical characterization of the adult patient with depression aimed at personalization of management.World Psychiatry. 2020 Oct;19(3):269-293. doi: 10.1002/wps.20771. World Psychiatry. 2020. PMID: 32931110 Free PMC article.
-
Mood and behavior regulation: interaction of lithium and dopaminergic system.Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1339-1359. doi: 10.1007/s00210-023-02437-1. Epub 2023 Feb 27. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36843130 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical